Evidence map›Paper›PMID 34299458›Full record

ReviewMolecules (Basel, Switzerland)2021

Challenges and Progress in Nonsteroidal Anti-Inflammatory Drugs Co-Crystal Development.

Ilma Nugrahani, Rismaya Desti Parwati

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Non-Covalent Reactions Supporting Antiviral Development.Molecules (Basel, Switzerland) · 2022
    Review
  15. Lipase Assisted (Pharmaceuticals (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ilma NugrahaniDepartment of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia.ORCID 0000-0001-5069-0343
Rismaya Desti ParwatiDepartment of Pharmacochemistry, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia.
Bandung Institute of Technology · ID

Funding

Lembaga Penelitian dan Pengabdian Kepada Masyarakat 147/IT1.B07.1/TA.00/2021
6 · The paper itself

Abstract

Co-crystal innovation is an opportunity in drug development for both scientists and industry. In line with the "green pharmacy" concept for obtaining safer methods and advanced pharmaceutical products, co-crystallization is one of the most promising approaches to find novel patent drugs, including non-steroidal anti-inflammatory drugs (NSAID). This kind of multi-component system improves previously poor physicochemical and mechanical properties through non-covalent interactions. Practically, there are many challenges to find commercially viable co-crystal drugs. The difficulty in selecting co-formers becomes the primary problem, followed by unexpected results, such as decreased solubility and dissolution, spring and parachute effect, microenvironment pH effects, changes in instability, and polymorphisms, which can occur during the co-crystal development. However, over time, NSAID co-crystals have been continuously updated regarding co-formers selection and methods development.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalChemistry, PharmaceuticalCrystallizationDrug DiscoveryPharmaceutical PreparationsSolubilityAnti-Inflammatory Agents, Non-SteroidalPharmaceutical Preparationschallengesco-crystalmulticompoentNSAIDprogresssalt co-crystal

Identifiers

PMID34299458
PMCPMC8303568
OpenAlexW3182208140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.